Non Invasive Neurostimulation Devices Global Market Report 2025

The non-invasive neurostimulation devices market size is expected to see rapid growth in the next few years. It will grow to $3.06 billion in 2029 at a compound annual growth rate (CAGR) of 12.8%. The forecasted growth can be linked to the rising aging population, increased use of wearable neurostimulation devices, growing healthcare spending, favorable government initiatives, and broader use in mental health care. Key emerging trends include a transition to minimally invasive stimulation techniques, innovations in wireless neurostimulation devices, greater integration with telehealth platforms, the development of closed-loop systems, and a growing emphasis on personalized neurostimulation approaches.

The increasing prevalence of neurological disorders is expected to propel the growth of the non-invasive neurostimulation devices market going forward. Neurological disorders are medical conditions that affect the brain, spinal cord, and nerves, leading to a range of symptoms including cognitive, motor, and sensory impairments. The growing occurrence of these conditions is closely linked to the aging global population, as aging gradually impairs neuronal function, reduces brain plasticity, and elevates oxidative stress, contributing to the development and progression of neurological issues. Non-invasive neurostimulation devices assist in diagnosing neurological disorders by delivering targeted stimulation to assess neural responses. They provide non-surgical, real-time evaluation methods, improving diagnostic accuracy and enhancing patient care in both clinical and home settings. For example, in July 2024, the National Health Service, a UK-based government agency, reported 487,432 patients diagnosed with dementia - a progressive brain disorder affecting memory, thinking, and daily activities - by June 30, 2024, marking an increase of 3,155 cases compared to May 31, 2024. This rise in neurological disorders is thereby contributing significantly to the growth of the non-invasive neurostimulation devices market.

Major companies operating in the non-invasive neurostimulation devices market are focusing on developing advanced products such as personalized stimulation protocols to enhance treatment effectiveness and patient outcomes. Personalized stimulation protocols involve tailoring neurostimulation settings to an individual’s specific medical condition, neural response, and treatment goals to maximize therapeutic benefits while minimizing side effects. For instance, in October 2023, Sooma Medical, a Finland-based medical technology company, introduced a remote clinician-monitored brain stimulation system designed for at-home treatment using non-invasive transcranial direct current stimulation (tDCS). This innovative solution enables healthcare professionals to supervise therapy sessions remotely, improving accessibility and treatment adherence for patients with neurological and mental health conditions like depression and chronic pain.

In December 2024, ElectroCore Inc., a US-based medical technology company, acquired NeuroMetrix Inc. for an undisclosed amount. This acquisition allowed ElectroCore to expand its portfolio in non-invasive neuromodulation by incorporating NeuroMetrix’s Quell pain relief device and DPNCheck diagnostic tool, strengthening its position in the field of bioelectronic medicine. NeuroMetrix Inc. is a US-based neurotechnology company that specializes in non-invasive neurostimulation devices.

Major players in the non invasive neurostimulation devices market are Boston Scientific Corporation, Alpha-Stim, Neurosoft Bioelectronics SA, Neuronetics Inc., BrainsWay Ltd., eNeura Inc., MagVenture A/S, Nexstim Plc, Neuroelectrics Barcelona S.L.U., Cefaly Technology, ElectroCore Inc., Brainbox India Private Limited, Flow Neuroscience AB, Fisher Wallace Laboratories Inc., Sooma Medical, Aleva Neurotherapeutics SA, NeuroSigma Inc., Mind Alive Inc., TheBrainDriver LLC, and Caputron Medical Products LLC.

North America was the largest region in the non invasive neurostimulation devices market in 2024. The regions covered in non-invasive neurostimulation devices report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the non-invasive neurostimulation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-invasive neurostimulation devices market consists of revenues earned by entities by providing services such as pain management therapy, cognitive enhancement programs, rehabilitation support, mental health treatment, and remote patient monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-invasive neurostimulation devices market also includes sales of transcranial magnetic stimulators (TMS), transcranial direct current stimulators (tDCS), vagus nerve stimulators (non-implantable), external trigeminal nerve stimulators (eTNS), and wearable neurostimulators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Non-invasive neurostimulation devices are advanced medical technologies developed to influence neural activity without the need for surgical procedures. These devices utilize external techniques such as electrical, magnetic, or ultrasonic stimulation to focus on particular regions of the nervous system. Their primary objective is to treat neurological and psychiatric disorders like chronic pain, depression, and epilepsy by modifying brain or nerve activity in a safe and efficient manner.

The primary categories of non-invasive neurostimulation devices include transcutaneous electrical nerve stimulation (TENS), transcranial magnetic stimulation (TMS), electromagnetic stimulation (EMS), and others. TENS involves the use of low-voltage electrical pulses delivered through the skin using electrodes as a method for non-invasive pain relief. These devices are employed across a variety of clinical applications such as pain management, neurological and psychological disorders, among others. They serve different end users including hospitals and clinics, homecare settings, and academic or research institutions.

The non invasive neurostimulation devices market size has grown rapidly in recent years. It will grow from $1.67 billion in 2024 to $1.89 billion in 2025 at a compound annual growth rate (CAGR) of 13.1%. This growth during the historic period can be credited to a rise in neurological disorder cases, increased awareness about neurostimulation therapies, heightened demand for non-invasive treatment methods, enhanced healthcare infrastructure, and a surge in neuromodulation-related research.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.